NMD Pharma at J. P. Morgan Healthcare Conference 2026
At the J. P. Morgan Healthcare Conference, we presented our progress in advancing novel therapies for neuromuscular diseases, with CEO Thomas Holm Pedersen delivering the presentation. The presentation highlighted our first-in-class ClC-1 inhibitor, ignaseclant (formerly known as NMD670), our differentiated muscle biology platform, and the clinical development of programs in Charcot-Marie-Tooth disease, spinal muscular atrophy, and myasthenia gravis.